EXSCIENTIA
15.6.2021 14:02:12 CEST | Business Wire | Press release
Exscientia, a clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The combination expands Exscientia’s translational capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues, rather than artificial cell lines or animal models. Allcyte’s platform has been validated on multiple solid and haematological tumour types as well as in non-cancerous tissues.
Pioneering work by Allcyte has delivered a platform able to anticipate the effectiveness of cancer treatments in the clinic by using AI to analyse the activity of drugs in live patient samples at single-cell resolution. In the first-ever1 prospective interventional study of its kind, EXALT-1, Allcyte’s approach predicted which therapy was to be most effective for late-stage haematological cancer patients based on drug activity in their own tissue samples. EXALT-1 demonstrated the real-world patient selection capabilities of Allcyte’s platform by achieving a 55% overall response rate and statistically significant improvement in progression free survival over the prior line of therapy. In a post hoc analysis, patients receiving therapy recommended by the platform showed significantly improved outcomes compared to their prior treatments (clinical benefit hazard ratio of 0.53; p=0.005), whereas patients who received treatments other than the platform recommended therapy showed worse outcomes (clinical benefit hazard ratio of 1.4; p=0.4)2 .
By joining Exscientia, Allcyte’s platform will be significantly expanded and extended into early discovery so that these ground-breaking technologies are applied from target discovery and drug optimisation to patient selection. This end-to-end approach will allow discovery projects to be assessed in a biological setting that more accurately reflects the actual patient environment, improving translation from laboratory to clinic.
“Allcyte is able to demonstrate what therapy actually works in the individual patient with the most disease relevant screening platform we have seen,” said Andrew Hopkins, Exscientia’s CEO. “Combining Allcyte’s platform with Exscientia’s technologies can redefine how drugs are developed, enabling integrated discovery and patient selection. Allcyte has assembled an outstanding team in Vienna and integration of the two platforms truly allows us to build our vision of patient-first AI.”
Commenting on the acquisition, Nikolaus Krall, Allcyte CEO added, “We are incredibly excited about the opportunity to immediately apply this technology to a wide range of drug discovery projects at Exscientia. This will also provide our team with the scale to expand our operations much more quickly to help provide important personalised, precision medicines to as many patients as possible.”
The transaction is currently being reviewed under the customary Austrian regulatory process prior to closing. Under the terms of the merger agreement, Exscientia will pay €50 million, comprising cash and Exscientia ordinary shares. Exscientia plans to expand the Vienna site as its hub in the European Union.
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
About Allcyte
Allcyte is a Vienna, Austria-based precision medicine company whose mission is to ensure that every cancer patient gets the best possible treatment. Allcyte’s technology is designed to select the most promising drug candidates for clinical development in the right patient populations to maximise clinical study success rates and patient benefit. Clinically, Allcyte’s goal is to provide physicians with actionable insights on how to treat cancer patients with the right drug at the right time in situations where classical genetics-driven precision medicine does not give precise answers. This is achieved by measuring functional anticancer drug activity in viable, primary human patient tissues at the single cell resolution to gain a preview of likely clinical efficacy. Allcyte’s technology is the first AI platform to successfully improve cancer patient outcomes in a clinical trial.
For more information on the EXALT-1 trial, refer to
[1] the following Lancet Haematology article; https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30208-9/fulltext
[2] the following ASH abstract; https://ash.confex.com/ash/2020/webprogram/Paper140831.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005584/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global styrker sin tilstedeværelse i Argentina med Fidem Partners30.9.2026 15:20:00 CEST | Pressemeddelelse
Andersen Global udvider sine kompetencer inden for skat og transaktioner i Argentina gennem en samarbejdsaftale med Fidem Partners og styrker dermed sin tilstedeværelse og sit serviceudbud på markedet. Fidem Partners blev stiftet i 2011 og rådgiver virksomheder om skat og compliance, fusioner og opkøb samt outsourcing af forretningsprocesser. Firmaet betjener virksomheder inden for energi, teknologi, finansielle tjenester, landbrug og forbrugsvarer og har stor erfaring med at rådgive datterselskaber af multinationale virksomheder i Argentina. Det bredt sammensatte team trækker på erfaring fra førende rådgivningshuse og erhvervslivet for at hjælpe virksomheder gennem de vigtigste udviklingsfaser. "Det meste af vores arbejde udfører vi for datterselskaber af multinationale virksomheder, der opererer i Argentina, hvor de regulatoriske rammer kræver dømmekraft – ikke kun compliance," udtalte Darío H. Díaz, managing partner hos Fidem Partners. "Samarbejdet med Andersen Global giver vores kl
Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape30.9.2026 15:00:00 CEST | Press release
Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders. Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions. "You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clien
Blackfuel Emerges From Stealth with More Than $250 Million in Contracted Revenue to Build a Global AI Token Grid30.9.2026 15:00:00 CEST | Press release
First deployment scheduled to enter service in 2026, combining industrial-scale infrastructure, proprietary inference software and long-term customer commitments. Blackfuel today emerged from stealth with more than $250 million in contracted revenue under multi-year customer agreements, unveiling its ambition to build a global AI Token Grid. Pioneering the AI Token Grid, Blackfuel is building a network of architecture-specific accelerator clusters connected through a common software and commercial layer, designed to turn dedicated compute into measurable, reservable AI output. By collaborating with AMD and NTT DATA, Blackfuel is developing its European-operated inference capacity, beginning with a GPU cluster currently being delivered in Europe. "The cloud was built around virtual machines. The next infrastructure layer will be built around tokens. We are building Blackfuel to become one of the world's defining AI compute companies, starting with our first deployments in Europe. That m
934 Embeds Bluefin Payment Security into Juno to Advance Secure, Connected Hospitality Payments30.9.2026 15:00:00 CEST | Press release
Partnership brings PCI-validated P2PE and tokenization into 934’s connected hospitality payment infrastructure Bluefin, a global leader in payment and data security, and 934, a global provider of connected payment technology for the hospitality industry, today announced a partnership to integrate Bluefin’s payment security capabilities into Juno, 934’s hospitality payment platform. Hospitality businesses increasingly operate across connected payment environments spanning hotels, restaurants, resorts and other guest experiences. Behind those interactions are multiple systems, workflows and payment technologies that must work together while protecting sensitive payment data. Juno is designed to connect those experiences through a unified hospitality payment environment. By incorporating Bluefin’s security technology into the platform architecture, 934 can provide customers globally with access to PCI-validated point-to-point encryption (P2PE) for card-present payments and tokenization fo
Visioneering Technologies' New Contact Lens Trial Shows Landmark Results in Slowing Children's Nearsightedness30.9.2026 14:59:00 CEST | Press release
Completed three-year PROTECT randomized controlled trial finds NaturalVue Multifocal 1 Day contact lens slowed myopia progression by 1.06 diopters and eye elongation by 0.58 mm at 36 months.1,2 Visioneering Technologies, Inc. (VTI), a medical device company that designs and markets specialty contact lenses, will announce completed three-year results from PROTECT, a prospective, double-masked, multinational randomized controlled trial evaluating the company's NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens for slowing the progression of myopia, or nearsightedness, in children. Ashley Tuan, OD, MS, PhD, VTI's Chief Medical Officer, will present the full findings at the American Academy of Optometry's annual meeting in Anaheim. Myopia develops when a child's eye grows too long, causing distant objects to appear blurry, and it typically worsens through childhood. Faster progression is associated with a higher lifelong risk of more serious eye conditions, including retinal detachmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom